What would you like to find?

Wellness since 1983

Ayugen Statin Induced Myopathy Risk Test

AyuGen Biosciences Pvt. Ltd. performs molecular genetic testing to detect presence of common genetic changes (or variation) in SLCO1B1 (also known as OAT1B1 – organic anion transporting polypeptide 1B1) which is an influx transporter that moves active statin acid from the blood stream into the liver.

Statins are a commonly prescribed drug used for cholesterol reduction and control. Variations in SLCO1B1 gene causes decreased transporter activity resulting in increased statin blood levels and therefore increase in the risk of adverse effects, such as myopathy (skeletal muscle toxicity), myalgia and rhabdomyolysis. Approximately 1-5 percent of individuals who are on statins may experience a dose-dependent adverse effect.

SLCO1B1 genotyping test detects a common variant that reduces the function of the transporter, resulting in an increased plasma concentration of the statins.

SLCO1B1-based dosing guidelines for statins recommends that clinicians should consider genotyping patients who are initiating statin therapy or those who have experienced adverse effects to statins in the past.

Are you taking any statins for reducing cholesterol?

This test will assess your risk for developing muscle problems (myopathy) due to statins.

This test looks for genetic variation in SLCO1B1 gene which is involved in moving active statin acid from the bloodstream into the liver. Statins are a commonly prescribed drug used for cholesterol reduction and control yet patient compliance remains a significant problem. Variations in SLCO1B1 results in decreased transporter activity that causes increased statin blood levels. Higher amount of statins in blood causes higher risk of adverse effects, such as myopathy (skeletal muscle toxicity), myalgia and rhabdomyolysis.

SLCO1B1 genotyping test detects a common variant that reduces the function of the transporter, resulting in an increased plasma concentration of the statins. The test improves the ability to prescribe the right drug type in the right dose according to a patient’s identified SLCO1B1 genotype.

The turn-around-time is about 5 to 7 days.

Sample requirement – 2ml Blood in EDTA tube/Saliva Sample